IQVIA
4820 Emperor Boulevard
Durham
North Carolina
27703
United States
Tel: 866-267-4479
Website: https://www.iqvia.com/
780 articles about IQVIA
-
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
4/15/2024
IQVIA Holdings Inc. will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024.
-
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
4/8/2024
IQVIA and Salesforce announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.
-
IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024
3/6/2024
IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m. ET.
-
IQVIA Publishes its 2023 Environmental, Social and Governance Report
2/26/2024
IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report.
-
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
2/23/2024
Global biopharma R&D productivity rebounded in 2023 with higher composite success rates enabled by industry-wide and regulator adoption of data and technology driven innovation, including novel trial design, optimized biomarker use, and digital and decentralized trial methodologies.
-
IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024
2/21/2024
IQVIA Holdings Inc., announced that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m. ET.
-
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
2/14/2024
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2023.
-
IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year
2/6/2024
IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year.
-
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
1/24/2024
IQVIA Holdings Inc. will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024.
-
Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report
1/17/2024
Global spending and demand for medicines will increase over the next five years to approximately $2.3 trillion by 2028 as more patients get access to new and better medicines, according to a new report from the IQVIA Institute for Human Data Science titled, “The Global Use of Medicines 2024 – Outlook through 2028.”
-
Kubota Vision Announces Vendor Agreement with IQVIA for eyeMO
12/6/2023
Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced the execution of a vendor agreement between Kubota Vision and IQVIA Services Japan G.K. for eyeMO, a portable, low-cost, home-based, remote and in-office ophthalmic OCT*1 device for monitoring of retinal diseases.
-
IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year
11/29/2023
IQVIA™ today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.
-
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes - November 15, 2023
11/15/2023
IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc., priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029, which was upsized due to strong demand.
-
IQVIA Announces Offering of Senior Secured Notes - November 14, 2023
11/14/2023
IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc., intends to raise $500,000,000 through an offering of senior secured notes due 2029.
-
IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree
11/6/2023
IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list.
-
IQVIA Reports Third-Quarter 2023 Results
11/1/2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2023.
-
A Discussion with IQVIA’s Michelle Gyzen Sr. Director, Regulatory Affairs and Drug Development Solutions
-
IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission
10/11/2023
IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations announced a strategic collaboration to advance the 100 Days Mission.
-
IQVIA Appoints Richard Staub III President of Research & Development Solutions
9/26/2023
IQVIA™ announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions business unit.
-
IQVIA Named a Leader in Pharmacovigilance Solutions in IDC MarketScape Report
9/12/2023
IQVIA™ has been named a Leader in the IDC Marketscape Worldwide Life Science R&D Pharmacovigilance Solutions 2022 Vendor Assessment.